Clinical Trial

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-05.
Trial Details
NCT Number NCT07335328
Lead Sponsor Medical College of Wisconsin
Conditions B-cell Non Hodgkin Lymphoma
Enrollment 24 participants
Start Date 2026-09-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2031-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-11